🔎 Trials Near Me

Home › Tumor sa Utak › Illinois

Pag-aaral pangklinika para sa Tumor sa Utak sa Illinois

14 pag-aaral para sa Tumor sa Utak ang naghahanap ng mga kalahok sa mga site sa Illinois.

Mga Lungsod sa Illinois

Opisyal na teksto ng pag-aaral (English)

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

  • Saint Anthony's Health, Alton
  • Rush - Copley Medical Center, Aurora
  • Illinois CancerCare-Bloomington, Bloomington
  • at 33 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT04511013

Frameless Stereotactic Radiosurgery for Intact Brain Metastases

  • University of Chicago, Chicago
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT02747303

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

  • Carle Cancer Center, Urbana
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT05386108

A Phase 1/1b Study of IAM1363 in HER2 Cancers

  • University of Chicago, Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06253871

Targeted Pediatric High-Grade Glioma Therapy

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Nagre-recruitObservasyonal na pag-aaral
12 Months – 39 Years · Lahat ng kasarian · Na-update Set 8, 2026 · NCT05839379

Study of Olutasidenib and Temozolomide in HGG

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Nagre-recruitPhase 2
Edad 12 hanggang 39 · Lahat ng kasarian · Na-update Set 1, 2026 · NCT06161974

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

  • Robert H. Lurie Comprehensive Cancer Center Northwestern University, Chicago
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 21, 2026 · NCT06764940

Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).

  • Lurie Children's Hospital, Chicago
Nagre-recruitPhase 2
Edad 1 hanggang 26 · Lahat ng kasarian · Na-update Ago 4, 2026 · NCT07680439

REMASTer: REcurrent Brain Metastases After SRS Trial

  • University of Chicago, Chicago
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 18, 2026 · NCT05124912

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

  • Decatur Memorial Hospital, Decatur
  • HSHS Saint Elizabeth's Hospital, O'Fallon
  • Methodist Medical Center of Illinois, Peoria
  • at 2 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 9, 2026 · NCT03550391

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Nagre-recruitPhase 2
12 Months – 39 Years · Lahat ng kasarian · Na-update May 29, 2026 · NCT05843253

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

  • Northwestern Memorial Hospital, Chicago
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 13, 2026 · NCT06810544

Intraoperative Fluorescence-Guided Aspirate Tissue Monitoring of 5-ALA During Brain Tumor Surgery

  • University of Illinois at Chicago, Chicago
Nagre-recruit
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Nob 12, 2025 · NCT07111182

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

  • John H Stroger Jr Hospital of Cook County, Chicago
  • Decatur Memorial Hospital, Decatur
  • Loyola University Medical Center, Maywood
  • at 1 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 8, 2025 · NCT03418961

Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.